The Second Event of the 7th Annual diaTribe Musings Panel Discussions
Past Event: Thursday, September 1, 2022
5:30-6:45pm EDT / 2:30-3:45pm PDT
As new and exciting T2D therapies become available, more and more people with T2D are able to achieve previously unattainable levels of glucose management. New medications, new means of delivering care virtually and continuously, and advances bariatric surgery are allowing individuals to lower their A1c, achieve greater Time in Range, and lose an amount of weight that in itself improves metabolic health.
So, what does the future look like? How can increasing numbers of people with diabetes achieve the goal of lowering their glucose levels to those of people without diabetes?
This panel will explore some of the new tools available and discuss whether we have reached a stage where diabetes remission is possible for many.
Our highly-regarded speakers are Dr. Vanita Aroda, Brigham and Women's Hospital and Harvard Medical School; Dr. Leonard Glass, Eli Lilly and Company; Dr. Robert Ratner, Virta Health. The panel will be moderated by Dr. Alan Moses of The diaTribe Foundation.
Vanita Aroda, MD
Director of Diabetes Clinical Research, Brigham and Women's Hospital
Associate Professor of Medicine, Harvard Medical School
Vanita Aroda is the Director of Diabetes Clinical Research at the Brigham and Women's Hospital in Boston, MA, and is an Associate Professor of Medicine at Harvard Medical School. Dr. Aroda completed her training in Internal Medicine and in Endocrinology, Diabetes and Metabolism at the University of California San Diego, CA, USA. Dr. Aroda has an interest and published record in diabetes prevention and novel therapeutics in diabetes and weight management. She also has a strong interest in understanding therapeutic interventions in large multicenter clinical trials and their applicability and integration into care. Dr. Aroda has years of experience in clinical trial conduct and leadership, has served as an investigator on the National Institutes of Health-funded GRADE, D2d, and DPPOS studies, and as the national or international signatory Principal Investigator for multiple therapeutic clinical trials. Dr. Aroda serves on the Professional Practice Committee of the American Diabetes Association and on the international ADA-EASD Consensus Group for the Management of Hyperglycemia in Type 2 Diabetes.
Leonard Glass, MD, FACE
Vice President, Global Medical Affairs, Lilly Diabetes
Leonard Glass, MD, FACE, is Vice President of Global Medical Affairs at Eli Lilly and Company. He is an endocrinologist with special interest in physiology, the insulin resistance syndrome, type 2, and type 1 diabetes. Leonard started his career with Lilly USA in 2004 and has held several positions including leading the development of several compounds in early, and late stage, development, as well as leading the US Diabetes Medical Affairs organization. In 2015 he left Lilly to head Diabetes Development at Sanofi and in 2016, he returned to Lilly as the Diabetes Therapeutic Area Lead for Lilly International. In 2018, Dr. Glass joined the newly formed Clinical Development Design Hub where he built, and managed, a group responsible for the novel design and execution of Phase I-IV trials for diabetes and metabolism and in 2020 he assumed his current responsibilities, leading the Lilly Diabetes Global Medical Affairs organization. Leonard earned his Bachelor of Science in biology from the University of Miami and went on to receive his Doctor of Medicine from Eastern Virginia Medical School. He completed his Internal Medicine residency and Clinical Research Fellowship in Endocrinology, Diabetes and Metabolism at the University of Texas Health Science Center at San Antonio. Leonard is also a Fellow of the American Association of Clinical Endocrinology (FACE), which recognizes achievement and leadership in the field of endocrinology. Prior to joining Lilly, Leonard was Assistant Professor of Medicine at the University of Miami Miller School of Medicine. His research focus was studying methods of insulin sensitization and physiological characteristics of insulin resistance for which he was awarded NIH/NIDDK and AHA support and was actively involved in research as well as training medical residents and fellows.
Robert E. Ratner, MD
Medical Advisor and former Chief Medical Officer, Virta Health
Professor of Medicine, Division of Endocrinology, Diabetes and Metabolism, Georgetown University School of Medicine
Robert E. Ratner, MD has been actively involved in diabetes research, management, and policy for over 35 years. He is currently Professor of Medicine in the Division of Endocrinology, Diabetes and Metabolism in the Department of Medicine at Georgetown University School of Medicine in Washington, DC. His research activities have included 17 years as a P.I. for the NIH-sponsored Diabetes Prevention Program, for which he served on the Steering Committee. Additional NIH sponsored research has included the SANDS and Strong Heart Studies for American Indians, the GRADE Study, and the Georgetown University GCRC and CTSA. He has been involved in the development and subsequent approval of numerous drugs for the improved care of people with diabetes, including new insulin preparations, GLP-1 receptor agonists, DPP-4 inhibitors and SGLT-2 inhibitors. For five years, he served as the Chief Scientific and Medical Officer for the American Diabetes Association where he oversaw, research funding, publications, scientific meetings, and the development of the Standards of Care. Most recently, he served for two years as the Chief Medical Officer for Virta Health, a telehealth company providing nutritional care for people with type 2 diabetes with the goal of improving outcomes with diminished need for medication.
Alan Moses, MD, FACP
Independent Consultant and Board Chair, The diaTribe Foundation
Past Chief Medical Officer, Joslin Diabetes Center and Novo Nordisk
Dr. Alan Moses is an independent consultant for the pharmaceutical and biotechnology sector. Trained in internal medicine and endocrinology, he spent the major part of his academic career at Harvard doing bench and clinical research and clinical care and rising to a position of Professor of Medicine. Dr. Moses co-founded and directed the Clinical Investigator Training Program at Beth Israel Deaconess-Harvard Medical School-MIT. From 1998 to 2004, Dr. Moses served as Senior Vice President and Chief Medical Officer of the Joslin Diabetes Center with specific responsibility for the Joslin Clinic. He joined Novo Nordisk in 2004. During his 14 years at Novo Nordisk, Dr. Moses served in multiple roles beginning as Associate Vice President of Medical Affairs in the US and rising to the position of Senior Vice President and Global Chief Medical Officer working in Copenhagen. Dr. Moses earned his MD from the Washington University School of Medicine in St. Louis, worked for three years at the National Institutes of Health, completed his clinical endocrine/diabetes training at Tufts New England Medical Center, and studied Health Care Strategy at Harvard Business School. He retired from Novo Nordisk in June 2018. He has been a member of the Board of Directors of The diatribe Foundation since September 2018.
About diaTribe Musings
Previously known as Musings Under the Moon, when it was a single live event at the ADA Scientific Sessions, diaTribe Musings is now one of The diaTribe Foundation's most treasured ongoing virtual programs, engaging a diverse audience in thought-provoking dialogue and providing an opportunity to connect healthcare providers, business leaders, people living with diabetes, advocates, families, entrepreneurs, and policymakers. Musings tickets are complimentary thanks to the generous support of our sponsors. We welcome anyone interested in learning about the massive shifts and opportunities occurring in the world of diabetes. Please spread the word and share this event with anyone interested in learning more about diabetes. Join the conversation on Twitter with #diaTribeMusings.
Past Musings Events